Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 17/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | HTT | P42858 | 5/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26400213 | 0.92 | KDM4E (0.40) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL21105782 | 0.89 | MEN1 (0.39) | KDM4EMEN1KMT2ATDP1 | |
| SCHEMBL22837714 | 0.89 | MEN1 (0.39) | KDM4EMEN1KMT2ATDP1 | |
| SCHEMBL23696542 | 0.89 | MEN1 (0.39) | KDM4EMEN1KMT2ATDP1 | |
| SCHEMBL22837624 | 0.89 | MEN1 (0.39) | KDM4EMEN1KMT2ATDP1 | |
| SCHEMBL24765431 | 0.89 | KDM4E (0.38) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL24673567 | 0.88 | MEN1 (0.38) | KDM4EMEN1KMT2ATDP1 | |
| SCHEMBL22837693 | 0.85 | MEN1 (0.36) | KDM4EMEN1KMT2ATDP1 | |
| SCHEMBL24379906 | 0.85 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL22861672 | 0.85 | MEN1 (0.38) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885ALDH1A1 2776/4885MEN1 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.